Yan Leyfman
May 24, 2025, 19:52
Yan Leyfman: GLP-1 Receptor Agonists may Modestly Reduce the Risk of Developing Certain Cancers
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“GLP-1 receptor agonists – commonly used to treat diabetes and obesity – may modestly reduce the risk of developing certain cancers, including colon and rectal cancer.
Study Highlights:
- 170,030 adults with diabetes and BMI ≥30 kg/m² across 43 U.S. health systems (2013–2023)
- Half received GLP-1 receptor agonists; half received DPP-4 inhibitors
- Average age: 56.8 years | Avg BMI: 38.5 | ~50% women | ~14% Black
Key Findings:
- 7% lower risk of obesity-related cancers in GLP-1 group
- 8% lower all-cause mortality
- Women on GLP-1s saw:
- 8% ↓ risk of obesity-related cancer
- 20% ↓ all-cause mortality
- 16% fewer colon cancer cases
- 28% fewer rectal cancer cases
- No increased risk of any obesity-related cancers.”
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023